We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Telix Radiopharmaceutical Production Facility Buildout Commences MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX...
EAU Updates Guidance for PSMA-PET Imaging MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company...
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA MELBOURNE, Australia and LIÈGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix® MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the...
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...
Australian TGA Approves Illuccix® for Prostate Cancer Imaging MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.21 | -0.847457627119 | 24.78 | 25.07 | 24.22 | 435595 | 24.736696 | DE |
4 | 0.07 | 0.285714285714 | 24.5 | 25.8 | 20 | 1008323 | 24.91612655 | DE |
12 | 4.09 | 19.970703125 | 20.48 | 25.8 | 20 | 951542 | 23.07090014 | DE |
26 | 6.11 | 33.0985915493 | 18.46 | 25.8 | 17.03 | 1273667 | 20.43016975 | DE |
52 | 14.63 | 147.183098592 | 9.94 | 25.8 | 9.13 | 1180650 | 17.44628834 | DE |
156 | 16.67 | 211.012658228 | 7.9 | 25.8 | 3.55 | 1171287 | 10.98843515 | DE |
260 | 22.99 | 1455.06329114 | 1.58 | 25.8 | 0.755 | 978406 | 8.81522706 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions